JP2022507781A5 - - Google Patents
Info
- Publication number
- JP2022507781A5 JP2022507781A5 JP2021527836A JP2021527836A JP2022507781A5 JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5 JP 2021527836 A JP2021527836 A JP 2021527836A JP 2021527836 A JP2021527836 A JP 2021527836A JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- amino acid
- compound according
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106091A JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769946P | 2018-11-20 | 2018-11-20 | |
| US62/769,946 | 2018-11-20 | ||
| PCT/US2019/062302 WO2020106780A1 (en) | 2018-11-20 | 2019-11-19 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Division JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507781A JP2022507781A (ja) | 2022-01-18 |
| JP2022507781A5 true JP2022507781A5 (https=) | 2022-11-29 |
| JP7702866B2 JP7702866B2 (ja) | 2025-07-04 |
Family
ID=69005818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527836A Active JP7702866B2 (ja) | 2018-11-20 | 2019-11-19 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12209180B2 (https=) |
| EP (2) | EP4428142A3 (https=) |
| JP (2) | JP7702866B2 (https=) |
| KR (1) | KR20210094568A (https=) |
| CN (1) | CN113382985A (https=) |
| AU (1) | AU2019384136B2 (https=) |
| BR (1) | BR112021009673A2 (https=) |
| CA (1) | CA3120528A1 (https=) |
| CL (1) | CL2021001308A1 (https=) |
| CO (1) | CO2021007581A2 (https=) |
| EA (1) | EA202191430A1 (https=) |
| ES (1) | ES2984190T3 (https=) |
| IL (1) | IL283313B2 (https=) |
| MA (1) | MA53455B1 (https=) |
| MX (1) | MX2021005822A (https=) |
| MY (1) | MY206542A (https=) |
| PH (1) | PH12021551153A1 (https=) |
| SG (1) | SG11202105175WA (https=) |
| WO (1) | WO2020106780A1 (https=) |
| ZA (1) | ZA202103431B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3046537T3 (en) | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| IL283313B2 (en) * | 2018-11-20 | 2025-08-01 | Regeneron Pharma | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
| CN116390771A (zh) * | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| US20220143194A1 (en) | 2020-11-10 | 2022-05-12 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| CN116018160B (zh) * | 2021-11-02 | 2026-03-03 | 烟台迈百瑞国际生物医药股份有限公司 | 一种包含sn38的抗体药物偶联物中间体及其制备方法 |
| CN115594766A (zh) * | 2021-12-30 | 2023-01-13 | 辽宁键凯科技有限公司（Cn） | 一种缀合物及用其制备的抗体偶联药物 |
| CN115505028A (zh) * | 2022-09-16 | 2022-12-23 | 辽宁键凯科技有限公司 | 一种分支型聚乙二醇连接子及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| WO2001041704A2 (en) * | 1999-12-13 | 2001-06-14 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US6908934B2 (en) * | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| EP1398032A1 (en) * | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US20060020036A1 (en) | 2004-06-24 | 2006-01-26 | Luc Van Rompaey | Methods and compositions to promote bone homestasis |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| KR102337414B1 (ko) | 2013-12-16 | 2021-12-10 | 제넨테크, 인크. | 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트 |
| SG11201605437YA (en) * | 2014-01-27 | 2016-08-30 | Pfizer | Bifunctional cytotoxic agents |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| US20160324981A1 (en) * | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
| JP6514414B2 (ja) * | 2015-11-04 | 2019-05-15 | ボレアリス エージー | 多層ラミネートを生産するためのプロセス |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| ES3046537T3 (en) * | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| IL283313B2 (en) * | 2018-11-20 | 2025-08-01 | Regeneron Pharma | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
-
2019
- 2019-11-19 IL IL283313A patent/IL283313B2/en unknown
- 2019-11-19 WO PCT/US2019/062302 patent/WO2020106780A1/en not_active Ceased
- 2019-11-19 AU AU2019384136A patent/AU2019384136B2/en active Active
- 2019-11-19 CN CN201980089547.4A patent/CN113382985A/zh active Pending
- 2019-11-19 JP JP2021527836A patent/JP7702866B2/ja active Active
- 2019-11-19 ES ES19827877T patent/ES2984190T3/es active Active
- 2019-11-19 EA EA202191430A patent/EA202191430A1/ru unknown
- 2019-11-19 US US17/295,420 patent/US12209180B2/en active Active
- 2019-11-19 EP EP24186656.5A patent/EP4428142A3/en active Pending
- 2019-11-19 MY MYPI2021002708A patent/MY206542A/en unknown
- 2019-11-19 KR KR1020217018084A patent/KR20210094568A/ko not_active Ceased
- 2019-11-19 EP EP19827877.2A patent/EP3883926B1/en active Active
- 2019-11-19 MX MX2021005822A patent/MX2021005822A/es unknown
- 2019-11-19 SG SG11202105175WA patent/SG11202105175WA/en unknown
- 2019-11-19 BR BR112021009673A patent/BR112021009673A2/pt unknown
- 2019-11-19 CA CA3120528A patent/CA3120528A1/en active Pending
- 2019-11-19 MA MA53455A patent/MA53455B1/fr unknown
-
2021
- 2021-05-19 CL CL2021001308A patent/CL2021001308A1/es unknown
- 2021-05-20 ZA ZA2021/03431A patent/ZA202103431B/en unknown
- 2021-05-20 PH PH12021551153A patent/PH12021551153A1/en unknown
- 2021-06-10 CO CONC2021/0007581A patent/CO2021007581A2/es unknown
-
2024
- 2024-12-16 US US18/983,183 patent/US20250171622A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106091A patent/JP2025138724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507781A5 (https=) | ||
| JP7754361B2 (ja) | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| AU2015273098B2 (en) | Auristatin derivatives and conjugates thereof | |
| KR20240095316A (ko) | Bcma 단일클론 항체 및 항체-약물 접합체 | |
| JP7843731B2 (ja) | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート | |
| KR20210020015A (ko) | 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염 | |
| JP2023535598A5 (https=) | ||
| ES2758506T3 (es) | Péptidos citotóxicos y conjugados de estos | |
| RU2586885C2 (ru) | Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство | |
| JP2022542222A5 (https=) | ||
| JP2017518304A5 (https=) | ||
| JP2020520926A5 (https=) | ||
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP2017518359A (ja) | 親和性薬物コンジュゲート | |
| IL266202B2 (en) | Antibody-conjugated cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide γ receptors | |
| JP2013534528A (ja) | 脂質とコンジュゲートする抗体 | |
| JP2025510606A5 (https=) | ||
| US20250320310A1 (en) | A method for programmatically managing antibody disulfide bonds site-specific modification | |
| JP2025111561A (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| EP4626479A1 (en) | Compositions and methods for protein internalization | |
| JP2024528719A (ja) | コンジュゲート化試薬及びそのコンジュゲート | |
| KR20240132060A (ko) | 항-조직 인자 항체-약물 접합체를 포함하는 약학적 조성물 | |
| WO2024041541A1 (en) | A novel thiol reductant, method and use thereof | |
| WO2026092606A1 (zh) | 带有连接系统的抗体药物偶联物 | |
| WO2026067624A1 (zh) | 一种包含亲水基团的配体-药物偶联物及其在医药上的应用 |